Revised advice on use of imatinib for chronic myeloid leukaemia.
NICE guidance that imatinib be available to all patients newly diagnosed with chronic myeloid leukaemia has been welcomed by clinicians and patient groups. The drug is expected to transform the management of CML.
Campbell
Ken
K
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D010879:Piperazines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate